Abstract
Motor neuron disease (MND) is a group of neurodegenerative diseases characterised by adult-onset progressive degeneration of motor neurons, of which amyotrophic lateral sclerosis (ALS) is the most common. MND is clinically heterogenous with complex aetiology, being caused by or associated with over 40 different genes, along with multiple environmental risk factors. Although New Zealand has one of the highest incidence and mortality rates of MND globally, the reasons for this are yet to be determined.
In light of this lack of systematic genetic MND research in New Zealand, we sought to identify the frequencies of genetic variants in known MND-linked genes in people in New Zealand with MND. A total of 184 participants were enrolled; 149 with a clinical diagnosis of MND and 35 who were clinically unaffected but at risk of familial MND. Of the 149 affected, 128 had sporadic MND, and 21 had familial MND. Participants’ DNA was screened for genetic variation in 46 MND-associated genes using a combination of Sanger sequencing, Illumina single nucleotide polymorphism (SNP) microarray, repeat-primed PCR for C9orf72, and an Invitae gene panel.
Clinical phenotypes of participants with MND recapitulated the trends seen in European reference populations with both males, and individuals with spinal onset, having earlier disease onset. Thirty three of the 184 participants (17.9%) carried known pathogenic variants; the majority had C9orf72 hexanucleotide repeat expansion (24/34), and the remainder had previously reported pathogenic genetic variants in SOD1 (9/34; p.(Ile114Thr) and p.(Glu101Gly)). All NZ SOD1 p.(Ile114Thr) cases (n=4) were distantly related (identical-by- descent) to one another and a cluster of >30 MND cases from Australia with the same variant. Variants of interest were identified in 14 participants, of which splicing variants DCTN1:c.279+1G>C and ATP13A2 p.(Lys804=) are subject to ongoing study. Of the pathogenic variants, 48.4% were identified in pre-symptomatic unaffected individuals with a family history, highlighting the importance of offering cascade testing and symptom surveillance for families, particularly as gene-specific treatments are becoming available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MM was funded by a doctoral scholarship from the University of Auckland. ELS was supported by a Rutherford Discovery Fellowship from the Royal Society of New Zealand [15-UOA-003]. This work was also supported by grants from Dr. Amelia Pais-Rodriguez and Marcus Gerbich, Motor Neuron Disease NZ, Freemasons Foundation of New Zealand, Matteo de Nora, and PaR NZ Golfing. This work was supported by National Health and Medical Research Council of Australia (Ideas grant 2011120 to KLW and LH), Macquarie University (KLW), FightMND (KLW, LH) and Motor Neuron Disease Research Australia (LH). No funding body played any role in the design of the study, nor in the collection, analysis, or interpretation of data nor in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health and Disability Ethics Committee of New Zealand granted approval (Approval number 19/CEN/7).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Non-identifiable data produced in the present study are available upon reasonable request to the authors.
